Tachibana Kazutaka, Imaoka Ikuhiro, Yoshino Hitoshi, Kato Nobuaki, Nakamura Mitsuaki, Ohta Masateru, Kawata Hiromitsu, Taniguchi Kenji, Ishikura Nobuyuki, Nagamuta Masahiro, Onuma Etsuro, Sato Haruhiko
Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan.
Bioorg Med Chem Lett. 2007 Oct 15;17(20):5573-6. doi: 10.1016/j.bmcl.2007.07.090. Epub 2007 Aug 22.
Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified.
对雄激素受体(AR)纯拮抗剂CH4892280(4)进行了先导化合物优化研究。化合物6和7在二氢睾酮(DHT)的7α位侧链末端含有羧酸,在报告基因测定(RGA)中显示出部分激动活性。将甾体核心结构转化为17α-甲基睾酮得到化合物14,其显示出较弱的纯拮抗活性。通过插入苯环对侧链进行优化得到化合物22以及28 - 30,这些化合物在亚微摩尔浓度下显示出纯拮抗活性。明确了构效关系。